Inclusion Criteria:  Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under International Conference on Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age ≥18) prior to performing study procedure. Aged ≥ 18 years. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test ≤ 4 days before randomization. Currently hospitalized. Peripheral capillary oxygen saturation (SpO2) ≤ 94% or requiring supplemental oxygen on screening.  Exclusion Criteria:  Participation in any other clinical trial of an experimental treatment for COVID-19. Evidence of multiorgan failure. Mechanically ventilated for > 5 days. Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN). Creatinine clearance < 50 mL/min.